Buprenorphine and naloxone interactions in opiate-dependent volunteers

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 1, 1996, Pages 105-114

  Mendelson, John ^a   Jones, Reese T ^a   Fernandez, Isabella ^a   Welm, Susette ^a   Melby, Ann K ^a   Baggott, Matthew J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; NALOXONE; OPIATE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG WITHDRAWAL; FEMALE; HEROIN DEPENDENCE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; SUBLINGUAL DRUG ADMINISTRATION;

EID: 0029737372     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90173-3     Document Type: Article

References (40)

1. Johnson RE, Cone EJ, Henningfield JE, Fudala PJ. Use of buprenorphine in the treatment of opiate addiction; I: physiologic and behavioral effects during a rapid dose induction. Clin Pharmacol Ther 1989;46: 335-43.
2. Seow SS, Quigley AJ, Ilett KF, Dusci LV, Swensen G, Harrison-Stewart A, et al. Buprenorphine: a new maintenance opiate? Med J Aust 1986;144:407-11.
3. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology 1994;116:401-6.
4. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid addiction. J Am Med Assoc 1992;267:2750-5.
5. Ling W, Rawson RA, Compton MA. Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. J Psychoactive Drugs 1994;26:119-28.
6. Kosten TR, Morgan C, Kleber HD. Treatment of heroin addicts using buprenorphine. Am J Drug Alcohol Abuse 1991;17:119-28.
7. O'Connor JJ, Moloney E, Travers R, Campbell A. Buprenorphine abuse among opiate addicts. Br J Addict 1988;83:1085-7.
8. Nigam AK, Srivastava RP, Saxena S, Chavan BS, Sundaram KR. Naloxone-induced withdrawal in patients with buprenorphine dependence. Addiction 1994;89:317-20.
9. Chowdhury AN, Chowdhury S. Buprenorphine abuse: report from India. Br J Addict 1990;85:1349-50.
10. Ghodse AH. Analysis of epidemiological data on agonist-antagonist analgesics. Drug Alcohol Depend 1987;20:375-83.
11. Hammersley R, Lavelle T, Forsyth A. Buprenorphine and temazepam abuse. Br J Addict 1990;85:301-3.
12. Lavelle TL, Hammersley R, Forsyth A. The use of buprenorphine and temazepam by drug injectors. J Addict Dis 1991;10:5-14.
13. Sakol MS, Stark C, Sykes R. Buprenorphine and temazepam abuse by drug takers in Glasgow: an increase [letter]. Br J Addict 1989;84:439-41.
14. Strang J. Abuse of buprenorphine (Temgesic) by snorting [letter]. Br Med J 1991;302:969.
15. Robertson JR, Aidan V, Bucknall ABV. Buprenorphine: dangerous drug or overlooked therapy. Br Med J 1986;292:1465.
16. Robinson GM, Dukes PD, Robinson BJ, Cooke RR, Mahoney GN. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend 1993;33:81-6.
17. Skidmore CA, Robertson JR, Robertson AA, Elton RA. After the epidemic: followup study of HIV seroprevalence and changing patterns of drug use. Br Med J 1990;300:219-23.
18. Weinhold LL, Preston KL, Farre M, Liebson IA, Bigelow GE. Buprenorphine alone and in combination with naloxone in nondependent humans. Drug Alcohol Depend 1992;30:263-74.
19. Jasinski DR, Fudala PJ, Johnson RE. Sublingual versus subcutaneous buprenorphine in opiate abusers. Clin Pharmacol Ther 1989;45:513-9.
20. Moa G, Zetterstrom H. Sublingual buprenorphine as postoperative analgesic: a double-blind comparison with pethidine. Acta Anaesthesiol Scand 1990;34:68-71.
21. Olley JE, Tiong GK. Plasma levels of opioid material in man following sublingual and intravenous administration of buprenorphine: exogenous/endogenous opioid interaction? [letter]. J Pharm Pharmacol 1988;40:666-7.
22. Loimer N, Presslich O, Grunberger J, Linzmayer L. Combined naloxone/methadone preparations for opiate substitution therapy. J Subst Abuse Treat 1991;8:157-60.
23. Kosten TR, Krystal JH, Charney DS, Price LH, Morgan CH, Kleber HD. Opioid antagonist challenges in buprenorphine maintained patients. Drug Alcohol Depend 1990;25:73-8.
24. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 1988;43:72-8.
25. Strain EC, Preston KL, Liebson IA, Bigelow GE. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther 1992;261:985-93.
26. Department of Health and Human Services, Public Health Service, National Institutes of Health. Epidemiologic trends in drug abuse, vol 1. Highlights and executive summary. Washington, DC: US Government Printing Office, 1994:38.
27. McNair DM, Lorr M, Doppleman LF. Profile of mood states, San Diego: Educational and Industrial Testing Service, 1971.
28. McQuay HJ, Moore RA. Buprenorphine kinetics in humans. In: Cowan A, Lewis JW, editors. Buprenorphine: combatting drug abuse with a unique opioid. New York: Wiley-Liss, 1995:137-47.
29. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. The pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990:485-521.
30. Walsh SL, June HL, Schuh KJ, Preston KL, Bigelow GE, Stitzer ML. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology 1995;119:268-76.
31. Strain EC, Preston KL, Liebson IA, Bigelow GE. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J Pharmacol Exp Ther 1995;272:628-38.
32. Strain EC, Preston KL, Liebson IA, Bigelow GE. Precipitated withdrawal by pentazocine in methadone-maintained volunteers. J Pharmacol Exp Ther 1993;267:624-34.
33. Hambrook JM, Rance MJ. The interaction of buprenorphine with the opiate receptor: lipophilicity as a determining factor in drug-receptor kinetics. In: Kosterlitz HW, editor. Opiates and endogenous opioid peptides. Amsterdam: Elsevier North-Holland Medical Press, 1976:295-301.
34. Blachly PH. Naloxone for diagnosis in methadone programs. J Am Med Assoc 1973;224:334-5.
35. Judson BA, Himmelberger DU, Goldstein A. The naloxone test for opiate dependence. Clin Pharmacol Ther 1980;27:492-501.
36. Kanof PD, Aronson MJ, Ness R, Cochrane KJ, Horvath TB, Handelsman L. Levels of opioid physical dependence in heroin addicts. Drug Alcohol Depend 1991;27:253-62.
37. Peachey JE, Lei H. Assessment of opioid dependence with naloxone. Br J Addict 1988;83:193-201.
38. Zilm DH, Sellers EM. The quantitative assessment of physical dependence on opiates. Drug Alcohol Depend 1978;3:419-28.
39. O'Brien CP, Greenstein R, Ternes J, Woody GE. Clinical pharmacology of narcotic antagonists. Ann NY Acad Sci 1978;311:232-9.
40. Preston KL, Bigelow GE, Liebson IA. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology (Berl) 1988; 94:484-90.